MedTrace Logo

Prevention of Renal Complications of Diabetes With Thiamine

NCT01725412 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-11-12

No results posted yet for this study

Summary

Thiamine is a key component in the creation of physiologic anti-inflammatory mediators. Serum thiamine stores have been found to be deficient in diabetic patients. Thiamine deficiency may be a key pathological mechanism of inflammation that results in diabetic kidney and retinal injury. The investigators hypothesize that the repletion of a patient's thiamine by oral supplementation may result in reduced inflammation, and therefore reduced kidney injury.

Conditions

  • Diabetic Nephropathy

Interventions

DIETARY_SUPPLEMENT

Thiamine 300mg PO once daily

DIETARY_SUPPLEMENT

placebo

Sponsors & Collaborators

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Dr. Gudrun Caspar-Bell, MD · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-06-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01725412 on ClinicalTrials.gov